CRBU
Caribou Biosciences
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Caribou Biosciences plans to halt its CAR-T programs and cut jobs amid funding challenges, despite having an allogeneic lymphoma therapy ready for late-stage testingOct 11, 2026
- Caribou received FDA RMAT designation for CB-011 CAR-T therapyMar 31, 2026
- Caribou Biosciences announces positive data from CaMMouflage Phase 1 trial of CB-011 in multiple myelomaNov 3, 2025
- Caribou Biosciences announces positive data from ANTLER Phase 1 trial demonstrating efficacy and durability of Vispa-cel (CB-010), an allogeneic CAR-T cell therapy, on par with autologous CAR-T cell therapiesNov 3, 2025